• Explore /
  • Poster
  • / A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.

A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.

Abstract Poster

Authors

null

Manish R. Patel

Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota, FL

Manish R. Patel , Aung Naing , Howard A. Burris III , Chia-Chi Lin , Giuseppe Curigliano , Fiona Thistlethwaite , Anna Rachel Minchom , Paolo Antonio Ascierto , Filippo G. De Braud , Michael Cecchini , Wouter Hanekom , Richard C.A Sainson , Rosamund J Wilson , Sonia Quaratino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)

Clinical Trial Registration Number

NCT03829501

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2624)

DOI

10.1200/JCO.2021.39.15_suppl.2624

Abstract #

2624

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: R. Donald Harvey

First Author: Lauren Christine Harshman

Poster

2012 ASCO Annual Meeting

Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.

Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.

First Author: Judith Balmaña

First Author: Andrae L. Vandross